Exane Derivatives’s Teva Pharmaceuticals TEVA Stock Holding History

Exane Derivatives’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-55	Closed	-$516	–	922
2022 Q1	$516	Buy	+55	New	+$459	﹤0.01%	853
2021 Q4	–	Sell	-55	Closed	-$536	–	972
2021 Q3	$536	Hold	55	–	–	﹤0.01%	932
2021 Q2	$501	Sell	55 -10,979	-100%	-$116K	﹤0.01%	942
2021 Q1	$127K	Sell	11,034 -1,129	-9%	-$12.9K	0.04%	378
2020 Q4	$117K	Buy	12,163 +2,302	+23%	+$22.1K	0.03%	380
2020 Q3	$88.8K	Buy	9,861 +4,606	+88%	+$48.7K	0.03%	311
2020 Q2	$64.8K	Sell	5,255 -39,807	-88%	-$450K	0.02%	336
2020 Q1	$405K	Sell	45,062 -10,200	-18%	-$104K	0.11%	138
2019 Q4	$582K	Buy	55,262 +2,169	+4%	+$19.4K	0.11%	156
2019 Q3	$365K	Hold	53,093	–	–	0.07%	185
2019 Q2	$490K	Buy	53,093 +43,782	+470%	+$528K	0.09%	173
2019 Q1	$146K	Buy	+9,311	New	+$164K	0.03%	261
2017 Q4	–	Sell	-32,467	Closed	-$571K	–	638
2017 Q3	$571K	Buy	+32,467	New	+$731K	0.11%	128

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Exane Derivatives's TEVA Position: Q2 2022 in Review

Exane Derivatives sold out of Teva Pharmaceuticals (TEVA) in Q2 2022, closing a stake of 55 shares — an estimated $516 sold.

Exane Derivatives first reported a position in TEVA in Q3 2017 and held it in 13 quarters. The position peaked at $582K in Q4 2019. 456 funds tracked by Wall St. Rank hold TEVA as of Q2 2022.

Exane Derivatives reported no remaining Teva Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Exane Derivatives sold 55 Teva Pharmaceuticals shares in Q2 2022, an estimated $516.
Exane Derivatives first reported a position in Teva Pharmaceuticals in Q3 2017 and held it in 13 quarters.
Exane Derivatives's Teva Pharmaceuticals position peaked at $582K in Q4 2019.
456 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2022.

Based on Exane Derivatives's 13F filing for Q2 2022, filed 12 Jul 2022.